Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy